[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Nottingham\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":709},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,46,79,106,132,162,198,224,247,280,327,351,374,401,428,457,489,513,536,553,574,603,627,654,681],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639096","accessing-the-clarity-and-acceptability-of-recruitment-materials-for-a-study-on-thoracic-aortic-disease-surveillance-100639096",false,"NCT07574151","Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance","Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance: A Qualitative Feasibility Study.","ACCESS-TAD","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to read and understand English\n\nExclusion Criteria:\n\n* Individuals under 18\n* Individuals unable to provide informed consent\n* Individuals unable to read or understand English",true,"ALL","18 Years",{"count":22,"type":23},30,"ESTIMATED","OBSERVATIONAL","People who are invited to take part in health research are usually given written information, such as invitation letters, and information sheets. These documents are essential because they help people understand what the study involves and decide whether they want to take part. However, many studies have shown that research information is often too complex, too long, or written in technical language. This can make it difficult for people to fully understand the study and give informed consent.\n\nThis study aims to assess how clear, accessible, and acceptable draft research documents are for a proposed future doctoral study related to thoracic aortic disease. Thoracic aortic disease is a long-term condition that requires regular monitoring, and people in surveillance programmes may be invited to take part in research. It is therefore important that study information is clear, sensitive, and easy to understand.\n\nIn this study, staff and students from the University's School of Health Sciences will be asked to review draft recruitment materials. These materials include a study invitation, an information sheet, and interview guide. Participants will be asked to give feedback on how easy the documents are to read, whether the information is clear, whether the tone feels appropriate, and whether the amount of information feels reasonable.\n\nThe study will also use a standard readability tool to assess whether the documents are written at a level suitable for the public.\n\nThis research does not involve patients and is considered low risk. Its purpose is to improve research materials before they are used with patients, helping to support informed consent, reduce confusion, and improve ethical and inclusive research practice in future studies.",[27],"Thoracic Aortic Disease",[29,30,31,32],"Surveillance","Recruitment materials","Clarity","Acceptability","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2026-03-11",{"date":41,"type":23},"2026-08-12",{"name":43,"class":44},"University of Nottingham","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100644544","lifestyle-advice-in-cvd-100644544","NCT07672054","Lifestyle Advice in CVD","Perspectives and Experience of Patients From Minority Ethic Communities on Advice Provided About Diet and Lifestyle Advice in Management of Their Cardiovascular Disease","Inclusion Criteria:\n\n* Patients over the age of 18 years with a personal history of minority ethnicity (non-white) and a diagnosis of cardiovascular disease\n\nExclusion Criteria:\n\n* Patients with a personal history of white ethnicity Patients without a history of cardiovascular disease",{"count":54,"type":23},15,"Individuals living in the UK who are from ethnic minority communities have a higher risk of heart disease and strokes than white individuals. This risk arises from the social determinants of health. These include lifestyle factors such as diet, physical activity and smoking. Improving these lifestyle factors in individuals is an essential part of reducing the chances of heart attacks and stroke. Patients may have diets and lifestyles arising from their cultural and religious backgrounds but receive advice which is not aligned to their own customs and experiences. Receiving advice which is not relevant to their own types of diet and lifestyle customs may create difficulties for patients in managing their heart and circulation health. Moreover, the dissonance between advice given and patient-specific relevance may lead to poorer adherence to the recommendations made to manage their condition. This can lead to poorer health outcomes for these patients. In addition, they may be advised to adopt diets and behaviours which are not appropriate to their cultures and may be also difficult to put into practice. This is important because lifestyle advice aligned to a patient's existing diet, behaviours and cultural beliefs leads to improved control of these health conditions. Learning to provide dietary and lifestyle advice relevant to individual patients needs is an important skill for the clinicians caring for them.",[57,58,59,60,61,62],"Cardio Vascular Disease","Dietary Change","Dietary Behaviors","Diet Habits","Experience","Ethnicity",[64,65,62,66,67,68,69,70],"Diet","Cardiovascular disease","Behavioural change","Modification","Healthcare experience","Healthcare access","Medical education","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":37},{"date":75,"type":23},"2026-07-06",{"date":77,"type":23},"2027-01-31",{"name":43,"class":44},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100644519","closed-loop-tes-non-invasive-stimulation-100644519","NCT07671079","Closed-loop tES-non-invasive Stimulation","Closed-loop Non-invasive Stimulation for Improving Brain and Mental Health in Healthy Individuals","CLIBM","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Aged between 18 and 40\n* Good general health\n* Not consume alcohol 48 hours prior study visit\n* Not currently taking any medications (except contraceptive pills) or if on long-term medication for a non-neurological\u002Fnon-psychiatric condition (r.g. inhalers) to be considered otherwise healthy and stable with no symptoms\n* Be right handedness\n\nExclusion Criteria:\n\n* Inability to complete MRI\u002FFUS\u002FTMS\u002FtES safety questionnaire and \u002F or informed consent process.\n* Current or previous diagnosis of a neurological, neurosurgical, psychiatric disorders.\n* Other significant medical condition (specific details to be reviewed by the CI prior to inclusion).\n* Currently pregnant, breast feeding, or on planned pregnancy.\n* Medication intake (such as beta-blocker, glucocorticoids, anti-depressants, anti-inflammatory drugs in the last 7d).\n* Medication intake (such as beta-blocker, glucocorticoids, anti-depressants) in the last 7d that are likely to affect brain function.\n* Significant use of medication or recreational drugs that affect the nervous system.\n* Excessive consumption of alcohol (\\>2 alcohol beverages per day).\n* Known allergy to any required consumables (such as aquasonic gel).\n* History of anaphylaxis to any substance\n* Have tightly coiled, curly or voluminous texture hair type (e.g., hair type 3, 4, or afro hair).\n* Having skin disease or sensitive skin on or close to the head.","40 Years",{"count":22,"type":23},"INTERVENTIONAL",[91],"NA","The goal of this study is to establish if non-invasive closed-loop neuromodulation is an effective approach to enhance cognitive function in healthy 18-40 years old volunteers. The main questions it aims to answer are:\n\n* Can closed-loop stimulation increase stimulation effectiveness?\n* Can closed-loop focused ultrasound specifically engage with excitatory or inhibitory neural populations in the target structure as measured through MRS?\n* Can observed stimulation outcomes for FUS be predicted through connectome analysis and computational models of indirect changes?\n\nResearchers will compare different closed-loop options to their open-loop counterpart to see if closed-loop approaches can increase efficacy and reduce the variability of the stimulation compared to open-loop approaches.\n\nParticipants will:\n\n* Answer some questionnaires at the start of the study and after each intervention session.\n* Undertake a MRI scanning session.\n* Undertake one open-loop FUS session.\n* Undertake one tES session.\n* Undertake one closed-loop FUS sessions involving tES and FUS, followed by a MRI scanning\n* Undertake one sham FUS session\n* Attend one visit in person to assess eligibility through questionnaires and one cognitive task",[94],"Closed-loop Brain Stimulation",[96,97,98,99],"neuromodulation","electrical stimulation","transcranial low-intensity focused ultrasound stimulation","closed-loop neuromodulation",{"date":34,"type":37},{"date":102,"type":23},"2026-07",{"date":104,"type":23},"2027-12",{"name":43,"class":44},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100644174","surveillance-of-neonatal-endotracheal-tube-colonisation-100644174","NCT07664449","Surveillance of Neonatal Endotracheal Tube Colonisation","Surveillance Study of Endotracheal Tube Microbial Colonisation in Neonatal Intensive Care Units","NETT","Inclusion Criteria:\n\n* Infant of any gestational age (22 weeks gestation and upwards) who is expected to be intubated for more than 12 hours\n* All infants must have verbal or written informed consent from the parent\u002Fcarer\n* All infants must have a realistic prospect of survival as determined by the attending clinical team\n\nExclusion Criteria:\n\n* Infants that are not for active resuscitation\n* Infants that are undergoing end-of-life care\n* In situations where consent is not possible or provided",{"count":115,"type":23},80,"Babies in neonatal intensive care units (NICUs) sometimes need help breathing using a breathing tube (endotracheal tube, or ETT) connected to a breathing machine (ventilator). Over time, bacteria and other substances can build up on the inside of these tubes. This build-up may contribute to infections, inflammation, or breathing problems, but we do not fully understand how often this occurs or what is present within the tubes used in UK NICUs.\n\nThis surveillance study will collect breathing tubes that have been removed from babies who have been ventilated for more than 12 hours as part of their normal clinical care. No additional procedures or interventions will be performed on babies, and the tubes would otherwise be discarded.\n\nResearchers will examine the used tubes and any respiratory secretions (mucus) associated with them. Laboratory testing will identify any bacteria or other microorganisms present and analyse the chemical composition that has accumulated within the tubes and respiratory secretions. By studying these samples, we hope to better understand how breathing tubes become colonised over time and how this may relate to infection and lung health in newborn babies.\n\nThis study aims to identify the microorganisms that colonises ETT and map them in a contemporary UK neonatal cohort.\n\nThe information gained from this study may help improve infection surveillance, guide future research, and support the development of strategies to reduce complications associated with mechanical ventilation in vulnerable newborn infants.",[118,119],"Ventilation, Mechanical","Ventilation-Associated Pneumonia",[121,122,123,124],"ventilation","endotracheal tube colonisation","neonatal","biofilm colonisation","2026-06-17",{"date":127,"type":37},"2026-06-24",{"date":102,"type":23},{"date":130,"type":23},"2028-03",{"name":43,"class":44},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":89,"phases":142,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100641764","glycaemic-response-of-arabic-bread-100641764","NCT07652320","Glycaemic Response of Arabic Bread","Glycaemic Response to Arabic Bread Formulated With Alternative Flour Blends: A Comparison With Arabic Wheat Bread","Inclusion Criteria:\n\n* Participants will be adults living with overweight or obesity (Body Mass Index \\[BMI\\] \\> 25 kg\u002Fm²).\n* Participants will be of any gender.\n* Participants will be aged 18 to 65.\n* Participants will be from any sociodemographic background.\n* Participants will be able to provide informed consent.\n* Participants will be able to understand spoken and written English and be able to record their responses to questionnaires.\n\nExclusion Criteria:\n\n* Those with food allergies or intolerances to any of the study ingredients, including wheat, chickpeas, lentils, or peas, will not be eligible.\n* Individuals with a known diagnosis of metabolic or chronic health conditions, such as diabetes, insulin resistance, hypertension, or phenylketonuria, will be excluded due to the potential impact on glycaemic control and study outcomes.\n* Participants with a fasting blood glucose level of above 7.0 mmol\u002FL.\n* Use of medications that influence blood glucose levels (e.g., corticosteroids, antipsychotics, antiviral protease inhibitors) or substances that interfere with digestion and absorption (such as laxatives or fibre supplements) will result in exclusion.\n* Pregnant or breastfeeding individuals will not be included due to the physiological changes that may influence study outcomes.\n* Participants with implanted medical devices, including pacemakers, artificial organs, defibrillators, or joint replacements, will be excluded for safety considerations.\n* Anyone who has undergone major surgery or hospitalisation within the last 5 months will be deemed ineligible.\n* Individuals who have participated in another research study involving invasive procedures within the last 3 months will be excluded.","65 Years",{"count":141,"type":23},14,[91],"Bread remains one of the most widely consumed staple foods worldwide, with wheat flour serving as its traditional foundation. However, the widespread dependence on refined wheat-based bread has paralleled the rising prevalence of type 2 diabetes (T2D), partly owing to its high glycaemic index (GI), which results in rapid increases in blood glucose levels. Enhancing the nutritional quality of bread, therefore, represents an important target for dietary intervention.\n\nDeveloping alternative flour blends for bread production presents a potential strategy for improving glycaemic control and supporting glucose homeostasis. Accordingly, this clinical trial aims to determine whether the partial replacement of wheat flour with legume flours, including chickpea, pea, and lentil, in Arabic bread formulations can lower glycaemic responses compared with traditional Arabic wheat bread.",[145,146,147],"Overweight","Obesity","Glycaemic Response",[147,149,150,151,152,145,146,153,154,155],"Arabic Bread","Legume Flour","Wheat Flour","Postprandial Glucose","Satiety","Appetite","Crossover Study",{"date":72,"type":37},{"date":158,"type":23},"2026-06",{"date":160,"type":23},"2027-03-31",{"name":43,"class":44},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":89,"phases":172,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100590209","postoperative-electrical-muscle-stimulation-two-100590209","NCT06964438","Postoperative Electrical Muscle Stimulation Two","A Three-Arm Randomised Controlled Trial to Establish Effectiveness of NMES With or Without Protein Supplementation to Preserve Muscle Mass and Strength and Improve Functional Outcomes After Abdominal Surgery for GI Cancer","POEMS2","Inclusion Criteria:\n\n* Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)\n* MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery\n* Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital\n* Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery\n* Basic conversational spoken English language\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Upper GI (gastrointestinal) cancer requiring thoracotomy\u002Fthoracoscopy\n* Pre-existing neuromuscular disease (including Parkinsons disease)\n* Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device\n* Metal prostheses or other metal-work in either upper legs (hip\u002Fknee\u002Ffemur)\n* Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine\n* Inability to give informed consent\n* Disability preventing completion of ERAS after surgery (requiring Zimmer frame\u002Fwheeled frame\u002Fwheelchair to mobilise or bed-bound)\n* Peripheral vascular disease\n* Epilepsy\n* Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \\\u003C60 on screening visit\n* Pre-existing diagnosis of liver disease\n* Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)\n* Return to theatre for surgical complication within first 5-days post operation\n* History of rhabdomyolysis\n* Pregnancy\n* Deep vein thrombosis within past 6-months\n* Allergy to whey protein\n* Patient refusal of whey protein products on grounds of dietary requirements or intolerance\n* Participating in another clinical trial concurrently or within the last 6 months\n* Known infection with blood borne virus",{"count":171,"type":23},45,[91],"Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.\n\nThe investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.\n\nThe current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.",[175,176,177,178],"Surgery","Colorectal Cancer","Muscle Atrophy","Cancer Gi",[97,180,181,182,183,184,185,186,187,188,189],"neuromuscular electrical stimulation","NMES","rehabilitation","general surgery","colorectal surgery","laparotomy","laparoscopy","postoperative recovery","gastrointestinal cancer","gastrointestinal surgery","2026-06-10",{"date":192,"type":37},"2026-06-15",{"date":194,"type":37},"2025-06-05",{"date":196,"type":23},"2027-03-01",{"name":43,"class":44},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":18,"sex":206,"minAge":20,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100640526","exploring-the-link-between-menopause-glucose-control-and-frozen-shoulder-in-women-100640526","NCT07603089","Exploring the Link Between Menopause, Glucose Control, and Frozen Shoulder in Women","Exploring the Association Between Menopausal Status, Metabolic Health, and Frozen Shoulder in Women: a Cross-sectional Observational Study","MENO-FROST","Part 1\n\nInclusion criteria:\n\n• Any women \\> 18 years with a history of frozen shoulder diagnosed by a clinician\n\nExclusion criteria:\n\n• Any women without a clear previous diagnosis of frozen shoulder\n\nPart 2:\n\nInclusion criteria:\n\n* Perimenopausal women (self-assessment)\n* Aged 40-60 years\n* Diagnosed with FS within the last 12 months OR\n* Matched controls (women aged 40-60 years without FS).\n\nExclusion criteria:\n\n* Diabetes mellitus,\n* Thyroid dysfunction,\n* Secondary FS (e.g. posttraumatic),\n* Use of medications influencing hormonal or metabolic parameters (e.g. hormone replacement therapy \\[HRT\\].","FEMALE",{"count":208,"type":23},340,"Background\n\nFrozen shoulder (FS) is a common condition and affects how the shoulder moves, making it very stiff and sore. The shoulder joint becomes inflamed and tightened due to scarring in the joint called fibrosis. It can take years to get better, and for around 50% of individuals the symptoms last even longer. FS causes a profound negative impact on physical and mental health, including disturbed sleep, low mood, difficulty performing everyday activities and, in many cases, are unable to continue working. FS affects around 1 in 10 people, and almost twice as many women as men between the ages of 40-60 years, but it is unknown why. It is thought to either be related to changes in sex hormones during the menopause, or due to the way the body handles sugar and fat, which changes with the menopause. However, associations between the menopause transition and FS are not well established and previous evidence has been poor quality. Current treatments include physiotherapy, a steroid injection or surgery but none of these treat the underlying cause of FS. Women with FS said they would like to know why they developed FS and more early treatment options to avoid a long recovery or an operation.\n\nAim This study aims to understand if there is a link between the menopause, changes in blood sugar levels and FS in women.\n\nPlan In Part 1, women who have had FS will fill in an electronic questionnaire to give us information about their menopause status at the onset of FS, how long their symptoms lasted, what treatments they tried, and if they had any other health conditions. This will enable us to determine the relationship between the menopause and the onset of FS.\n\nIn Part 2, the investigators will invite 18 perimenopausal women with recently diagnosed FS and 18 matched women without FS to attend a one-day visit at the University of Nottingham. The investigators will measure their blood sugar levels over two weeks using a small monitor on their arm. The investigators will assess their menopause symptoms and shoulder related outcomes using validated questionnaires. The investigators will assess their shoulder movement and measure body fat and muscle levels, physical activity levels, diet, and take a blood sample to test sex hormones, inflammation and lipids, as well as markers related to frozen shoulder. This will help us to assess the relationship between blood glucose control and the onset of FS in perimenopausal women.\n\nImpact This research will help us understand if there's a link between menopause, blood sugar control, and FS. It could lead to new clinical trials testing treatments early in FS, such as a glucose lowering medication or hormone therapy, to help women recover faster and avoid surgery. This may improve clinical outcomes in women with FS and reduce costs associated with treating FS. This important question came directly from patients and has not been studied in depth before. The investigators plan to share the results widely through health newsletters, podcasts, research conferences, and medical journals.",[211],"Frozen Shoulder",[213,214,215],"frozen shoulder","menopause","glucose","2026-05-17",{"date":218,"type":37},"2026-05-22",{"date":220,"type":23},"2026-08",{"date":222,"type":23},"2027-09",{"name":43,"class":44},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":45},"100637388","learning-differences-in-medical-education-100637388","NCT07585708","Learning Differences in Medical Education","What Are the Patient and Medical Student Perspectives on the Learning Needs and Expectations of Training of Future Doctors in Healthcare for Individuals With Learning Differences?","Inclusion Criteria:\n\n* Volunteers will be recruited from participants in teaching sessions to GEM medical students held in September and October 2025. This will be using convenience sampling. Up to 120 students currently on the GEM Year 1 preclinical programme at the time of the study will be invited to complete the study.\n\nExclusion Criteria:\n\n* All who do not meet the inclusion criteria defined above",{"count":54,"type":23},"A learning difference or disability is a reduction in intellectual ability (GMC, 2024). It causes lifelong difficulty with everyday activities. Different individuals require different levels of support. Individuals with learning disability may also have learning difficulties and mental health problems, but these conditions do not always co-exist. Learning difficulties affect the way someone processes information. They are not related to intelligence but can affect learning and education. People with learning differences can experience higher rates of mental and physical ill-health. The individual's life expectancy is shorter than the average for the population. This is related to access and experience of health care. These patients may experience discrimination affecting their healthcare.\n\nDiscrimination arises from staff and organisational attitudes towards patients and judgements about their quality of life. These individuals' care is also at risk of diagnostic overshadowing where a patient's symptoms are attributed to their disability rather than a disease. Many people with learning disabilities may find it harder to use healthcare services, and the investigators want to find out what challenges these individuals face. For example, do these patient have trouble understanding what is being said to them? Are there issues with getting an appointment or understanding the information about their health?\n\nThis project focuses on understanding the experiences of people with learning disabilities when they use health services. How easily do can these individuals communicate with their clinician? Are there barriers in accessing care? Do these individuals feel respected and listened to during their appointments? How should healthcare staff be trained to provide better care to these patients? The investigators will be speaking directly to patients with learning disabilities living in Derbyshire. This will be by interviews encouraging the patients to share their thoughts and experiences. The information the investigators gather will help understand these people's experiences of healthcare and how this could be improved. The investigators will also undertake an anonymised survey of medical students on their perceived learning needs regarding individuals with learning differences. This information will be used to develop educational resources for clinical teachers. medical students and staff. Working with the volunteers will better prepare future doctors to provide holistic care for patients with learning differences.",[234,61,235],"Healthcare Access","Learning Disabilities",[237,238,68,69,70],"Learning difference","Learning disability","2026-05-13",{"date":241,"type":37},"2026-05-18",{"date":243,"type":23},"2026-05-07",{"date":245,"type":23},"2026-12-31",{"name":43,"class":44},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":19,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":258,"studyType":24,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":45},"100638525","diathermy-on-diabetes-glucose-monitoring-effectiveness-100638525","NCT07583238","Diathermy On Diabetes Glucose Monitoring Effectiveness","Assessing the Impact of Intraoperative Diathermy on Accuracy and Functioning of Glucose Monitoring Systems","DODGE","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus.\n* Planned admission for elective surgery at Nottingham University Hospitals NHS Trust.\n* Currently routinely using a prescribed Abbott Libre-2, Abbott Libre-3, Dexcom G6 or Dexcom G7 glucose monitoring system to monitor glucose concentrations.\n* Aged 4 years or older on the day of surgery.\n* Ability to give informed consent \u002F ability of parent\u002Fcarer to give informed consent (as appropriate).\n\nExclusion Criteria:\n\n* Use of paracetamol above maximum dose within 7 days before the scheduled date of surgery (in adults with body weight under 51kg - maximum of 60mg\u002Fkg per day, in adults with body weight 51kg and above - maximum of 4g per day, in children - maximum dose as per their age as stated in the British National Formulary for Children)\n* Any use of hydroxyurea within 7 days before the scheduled date of surgery\n* Use of more than 500mg per day of ascorbic acid \u002F vitamin C within 7 days before the scheduled date of surgery\n* Currently taking medications as part of a clinical trial.","4 Years",{"count":257,"type":23},126,"1 Day","The goal of this observational study is to investigate if diathermy (a surgical tool that uses electrical energy to control bleeding) has any affect on the accuracy and functioning of continuous glucose monitoring systems in adults and young people with Type 1 Diabetes. The main questions this study aims to answer is -\n\n\\- Does the accuracy of continuous glucose monitoring systems change after use of diathermy?\n\nParticipants will:\n\n* Have their height and weight checked.\n* Provide information about their medical history including type of diabetes, other medical conditions and any current medications they take.\n* Have paired glucose meter and sensor glucose measurements taken every 15-75 minutes from up to 4 hours before surgery until up to 4 hours after the end of surgery.\n* Have two blood samples taken to measure glucose levels, The first one will be before the use of diathermy and the second will be after the use of diathermy.",[261],"Type 1 Diabetes Mellitis",[263,264,265,266,267,268,269,270,271,272],"Continuous Glucose Monitoring Systems","Diathermy","Type 1 Diabetes Mellitus","Capillary blood glucose","Sensor blood glucose","Peri-operative care","Intra-operative T1DM management","pre-operative","post-operative","intraoperative","2026-05-06",{"date":239,"type":37},{"date":276,"type":23},"2026-05",{"date":278,"type":23},"2027-02",{"name":43,"class":44},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":19,"minAge":287,"maxAge":20,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":45},"100607055","effective-dosing-of-burosumab-in-xlh-100607055","NCT07183579","Effective Dosing of Burosumab in XLH","A Retrospective Observational Study of the Effect of Dosing Regimen of Burosumab on Biochemical Control of Serum Phosphate Levels in Patients With X-linked Hypophosphataemia (XLH)","Inclusion Criteria:\n\n* A diagnosis of x-linked hypophosphataemia (XLH) including genetic confirmation of a PHEX mutation.\n* Has received at least 12 months of continuous Burosumab treatment under paediatric criteria (given Burosumab is not started till a child is 12 months old in England, the minimum age will, therefore, be 2 years old) prior to their 18th birthday.\n\nExclusion Criteria:\n\n* Burosumab received under adult criteria (patients who have received both Burosumab under paediatric arrangements and, subsequently, adult arrangements, can have data obtained during paediatric dosing included).","2 Years",{"count":289,"type":23},120,"X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells. Low phosphate leads to soft bones (rickets). Patients experience bowed legs, short stature, bone pain and dental pain.\n\nPrior to Burosumab, conventional treatment of XLH previously consisted of two medications. On this regimen, patients take oral phosphate supplements 4-6 times a day and an active form of vitamin D daily. This treatment can leave patients with residual symptoms. They report significant disabilities and reduced quality of life.\n\nBurosumab (Crysvita, Kyowa Kirin) is now the standard paediatric treatment for XLH. It is given once a fortnight by injection under the skin. Early studies used a starting dose of 0.4mg\u002Fkg per dose. NICE recommends a starting dose of 0.4mg\u002Fkg, a normal maintenance dose of 0.8mg\u002Fkg and a maximum of 2mg\u002Fkg (up to 90mg). The British National Formulary for Children (BNFC) gives the same advice.\n\nHowever, the European Medicines Agency recommends a starting dose of 0.8mg\u002Fkg per dose which is, therefore, the standard starting dose now. Some patients achieve symptom and biochemical control on less than 0.8 mg\u002Fkg per dose. They may be exposed to higher doses than necessary.\n\nTo date, approximately 200 patients have started on Burosumab in England. They are all managed by specialist centres. The rare status of XLH means there are relatively few patients in each centre. Treatment effects and trends can only be described by collating data from multiple centres.\n\nThe investigators will undertake a review across multiple English centres of the doses of Burosumab. The review will only collect data already in the patients' health records. It will look at factors affecting the starting dose. The investigators will assess the association between dose, blood markers and growth.",[292],"X-linked Hypophosphatemia (XLH)",[294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318],"Hypophosphatemia, X-Linked Dominant","Rickets","Burosumab","Monoclonal Antibodies","Alkaline Phosphatase","Parathyroid Hormone","Retrospective Studies","Observational Study","Multicenter Study","Dose-Response Relationship, Drug","Child","Adolescent","Pediatrics","X-Linked Hypophosphatemia (XLH)","Metabolic Bone Disease","Crysvita","FGF23 Antibody","Real-World Evidence","Pragmatic Clinical Study","Serum Phosphate","Nephrocalcinosis","Paediatric Endocrinology","Treatment Outcome","Adverse Events","Drug Administration Schedule","2026-05-05",{"date":321,"type":37},"2026-05-11",{"date":323,"type":37},"2025-11-03",{"date":325,"type":23},"2026-07-01",{"name":43,"class":44},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":45},"100636738","improving-patient-assessment-after-acute-kidney-injury-aki-100636738","NCT07569588","Improving Patient Assessment After Acute Kidney Injury (AKI)","IMPACT-AKI","Inclusion Criteria:\n\nObservational study workstream\n\n* Age 18-85 years\n* AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission\n* 60-90 days after peak creatinine Qualitative interview workstream\n* Age 18-85 years\n* AKI during hospital admission\n* 60-90 days after peak creatinine Participatory workshop workstream\n* Age 18-85 years\n* Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community.\n\nExclusion Criteria:\n\nObservational study workstream\n\n* Inability to give informed consent\n* No baseline creatinine available in previous 12 months\n* Pregnancy or breastfeeding\n* Current treatment with dialysis\n* Renal transplant\n* Pacemaker in situ\n* Previous amputation\n* Allergy to Omnipaque contrast agent (WP1 only)\n* Manifest thyrotoxicosis (WP1 only)\n* Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \\>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream\n* Inability to give informed consent\n* No baseline creatinine available in previous 12 months\n* Current treatment with dialysis\n* Renal transplant\n* Receiving palliative care Participatory workshop workstream\n* Inability to give informed consent\n* Inability to communicate in English (the qualitative workshops will be held in English)","85 Years",{"count":336,"type":23},100,"The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:\n\n1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI?\n2. What are the experiences of patients after AKI?\n3. What interventions should be recommended to improve assessment and support of patients after AKI?\n\nParticipants will be asked to do one or more of:\n\n* blood tests to measure kidney function in different ways\n* have measurement of their body composition\n* complete questionnaires about their symptoms\n* have an interview with a researcher about their experiences\n* discussion to develop an action plan based on findings",[339],"Acute Kidney Injury",[341,342,343],"acute kidney injury","chronic kidney disease","patient reported outcome measures","2026-05-01",{"date":273,"type":37},{"date":347,"type":37},"2026-02-16",{"date":349,"type":23},"2029-10",{"name":43,"class":44},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":89,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":45},"100636457","effects-of-hiit-following-ptr-programme-100636457","NCT07565935","Effects of HIIT Following PTR Programme","Can High-Intensity Interval Training (HIIT) Reduce the Risk of Diabetes Relapse Following Discharge From the NHS Path to Remission Programme? - a Pilot Study","HIITpostLCD","Inclusion Criteria:\n\n* Adults between the age of 18-70 years\n* Ability to provide informed consent\n* Completed the NHS Path to Remission programme and achieved diabetes remission (HbA1c \\\u003C48mmol\u002Fmol (6.5%), and off diabetes medications for at least three months)\n\nExclusion Criteria:\n\n* BMI \\> 40kg\u002Fm2\n* Current participation in a formal exercise regime\n* Current pregnancy or breastfeeding\n* Uncontrolled hypertension (blood pressure \\>160\u002F100mmHg)\n* History of cardiovascular disease:\n\n  * Symptomatic angina\n  * Heart failure (class III\u002FIV)\n  * Significant arrhythmias\n  * Right to left cardiac shunt\n  * Recent acute coronary syndrome\n  * Severe aortic valvular disease\n  * Active cardiac infection\n* Background of the following respiratory diseases:\n\n  * Pulmonary hypertension\n  * Significant COPD\n  * Uncontrolled asthma\n* History of malignancy undergoing current treatment or palliation\n* Presence of significant musculoskeletal, neurological or cerebrovascular disease\n* Any other medical condition deemed by the investigators to preclude inclusion into the study","70 Years",{"count":361,"type":23},20,[91],"Caloric restriction programmes are highly effective and safe interventions for inducing rapid weight loss and improvements in glycaemic control. The landmark DiRECT study showed that 68% of people completing a caloric restriction intervention achieved remission of type 2 diabetes (T2D) by one year. Consequently, the NHS Path to Remission (PTR) programme was developed to stimulate diabetes remission in individuals that meet certain criteria. Unfortunately, long-term follow-up of the DiRECT study suggests that in the majority of participants that achieved remission, diabetes relapses within 5 years. This necessitates a focus on identifying methods to improve long-term maintenance of diabetes remission.\n\nHigh-intensity interval training (HIIT) involves several brief bursts of intense exercise, interspersed with recovery breaks, and is becoming increasingly popular. HIIT can cause improvements in cardiovascular fitness, reduce blood pressure, and lower body fat content in only a fraction of the time of traditional exercise methods. Specific to T2D, HIIT has been shown to improve pancreatic beta cell function, which is critically important for maintenance of long-term diabetes remission.\n\nThis pilot study is being conducted to determine whether participating in a home-based HIIT training programme may help maintain beta cell function in individuals that have achieved diabetes remission following the NHS PTR programme. The study will take place at the Royal Derby Hospital.\n\nThe intention is to recruit 20 participants from Derbyshire or Nottinghamshire that have achieved diabetes remission in the NHS PTR programme. Participants will be recruited following discharge from the programme and allocated to either perform a HIIT training programme (intervention group), or continue with usual care (control group) for 16 weeks.\n\nBefore starting, participants will attend the research department to have initial measurements taken including bioimpedance, fasting bloods, an intravenous glucose tolerance test, muscle ultrasound, electromyography and cardiopulmonary exercise testing. Following this, those in the intervention group will be asked to perform a home-based HIIT training programme 3 times per week and record details of each session in a booklet. The control group will be asked to continue with their habitual levels of physical activity. Participants will be contacted regularly to ensure their safety and compliance.",[365,366],"Obesity & Overweight","Type 2 Diabetes","2026-04-29",{"date":369,"type":37},"2026-05-04",{"date":276,"type":23},{"date":372,"type":23},"2027-05",{"name":43,"class":44},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":45},"100602197","an-exploration-of-sleep-disturbance-and-outcomes-in-tbi-sleep-tbi-100602197","NCT07120373","An Exploration of Sleep Disturbance and Outcomes in TBI (SLEEP-TBI)","An Exploration of the Relationship Between Sleep Disturbance, Mental Health, and Functional Outcomes in Mild, Moderate and Severe Traumatic Brain Injury (TBI): A Mixed Methods Study","SLEEP-TBI","Part 1\n\nInclusion criteria:\n\n* Age 18-60 years\n* Patients presenting to the Emergency Department within 24 hours of head injury\n* Medically diagnosed TBI of any severity\n* Glasgow Coma Scale (GCS) score documented on admission\n* Able to provide informed consent to take part in the study\n* To be able to wear an activity tracker for a period of 2 weeks, in usual home environment within 12 weeks of injury\n\nExclusion criteria:\n\n* Unable to understand the study requirements or give informed consent\n* Other diagnosed neurological condition such as, but not limited to, stroke, brain tumour, epilepsy, motor neuron disease, Parkinson's disease, or spinal cord injury\n* No definition of TBI or description of TBI severity, patient report only, or unknown time since injury\n* Pre-existing sleep disorder (self-reported or from clinical records)\n* Individuals that have working patterns that include night shifts\n* Not contactable via telephone, letter or email\n\nPart 2\n\nInclusion criteria:\n\n* Age 18-60 years\n* Medically diagnosed TBI of any severity\n* Glasgow Coma Scale (GCS) score documented in medical notes\n* Able to provide informed consent to take part in the study\n* TBI sustained \\>12 months\n* Able to wear an activity tracker in usual home environment for a period of 2 weeks\n\nExclusion criteria:\n\n* Unable to understand the study requirements or give informed consent\n* Other diagnosed neurological condition such as, but not limited to, stroke, brain tumour, epilepsy, motor neuron disease, Parkinson's disease, or spinal cord injury\n* No definition of TBI or description of TBI severity, patient report only, or unknown time since injury\n* Pre-existing sleep disorder (self-reported or from clinical records)\n* Individuals that have working patterns that include night shifts\n* Not contactable via telephone, letter or email\n\nPart 2 - For clinicians\n\nInclusion criteria:\n\n* A registered healthcare professional working at Nottingham University Hospitals Trust\n* Clinical experience of delivering rehabilitation services to participants with TBI that have been recruited to the study\n\nExclusion criteria:\n\n* Not contactable via telephone, letter or email\n* Unable to understand the study requirements or give informed consent\n\nPart 3\n\n• Inclusion\u002FExclusion criteria as stated above. 50% of participants will be recruited from Part 1, and 50% of participants will be recruited from Part 2 for both studies.","60 Years",{"count":384,"type":23},180,"This study aims to look at how sleep disturbance affects people who have had a traumatic brain injury.\n\nSleep disturbance can include waking frequently in the night, difficulty falling asleep, excessive sleepiness or changes to usual sleep patterns.\n\nInvestigators define traumatic brain injury as an injury caused by a forceful bump, blow, or jolt to the head or body, or from an object entering the brain. This results in a disturbance of normal brain function, that can be temporary.\n\nBy understanding the relationship between sleep disturbance and traumatic brain injury, investigators will hopefully improve care and treatment for people with a traumatic brain injury.\n\nInvestigators are looking to understand each participant's experience of sleep disturbance, as well as measuring sleep, using a device that monitors movement and sleep quality.\n\nInvestigators are interested how sleep disturbance impacts things like day-to-day life and activities, such as work or leisure. Investigators are also interested in mental health, such as depression or anxiety.",[387],"Traumatic Brain Injury",[389,390,391,392,393,394],"Sleep disturbance","Head injury","Traumatic brain injury","Sleep","Actigraphy","TBI",{"date":273,"type":37},{"date":397,"type":37},"2025-10-21",{"date":399,"type":23},"2026-12",{"name":43,"class":44},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":139,"enrollmentInfo":409,"targetDuration":4,"studyType":89,"phases":411,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":45},"100636725","early-phase-1-proof-of-principle-study-for-an-efficacy-trial-of-linaclotide-for-cystic-fibrosis-100636725","NCT07569419","Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis","A Randomised, Placebo-controlled Crossover Study Defining the Mode of Action of Linaclotide in Healthy Volunteers Using MRI","MODEL","Inclusion Criteria:\n\nParticipant is willing and able to give informed consent for participation in the study\n\nNot currently taking any medications (except for selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral contraceptive pill).\n\nAged between 18-60 years.\n\nAbility to conform to the study protocol, including overnight fasting, dietary and lifestyle restriction, administering linaclotide and placebo intervention, MRI scanning, consuming the rice pudding\u002Fblue dye meal, and rating stool frequency and appearance.\n\nExclusion Criteria:\n\nContraindication to MRI scanning (i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, unable to lie flat and relatively still for less than 5 minutes.)\n\nPregnancy, lactating, or planning pregnancy during the investigation declared by candidate.\n\nHistory declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function.\n\nReported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix).\n\nIntestinal stoma.\n\nAny medical condition that may potentially compromise participation in the study e.g., known food intolerance to rice pudding, known contraindication to the oral administration of linaclotide or placebo.\n\nHas a body mass index (BMI) value less than 18.5 or greater than 35.\n\nWill not agree to follow dietary and lifestyle restrictions required.\n\nUnable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study.\n\nParticipants who are currently (or in the past 3 months) taking antibiotics or probiotics as these may impact GI function.\n\nParticipation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM.\n\nAnyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse.\n\nHaving taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance\n\n\\-",{"count":410,"type":23},26,[412],"EARLY_PHASE1","Linaclotide is a medicine used to treat constipation and irritable bowel syndrome with constipation (IBS-C). It works by acting on the surface of the gut lining, where it increases the movement of salt and water into the bowel. This softens stools, makes them easier to pass, and can also reduce gut pain\n\nOne advantage of linaclotide is that, unlike some natural substances in the gut, it is stable and can act throughout the intestine. Studies in animals show that it has the strongest effect in the upper small intestine, but it may act in other parts of the bowel as well. In people, however, it is not yet clear whether linaclotide mainly works in the small intestine or in the large intestine (colon). Knowing this is important, because it could help the investigators understand whether linaclotide might also be useful in other conditions, such as cystic fibrosis, where the gut does not handle fluid properly.\n\nLinaclotide is taken as a capsule, but less than 1% is absorbed into the bloodstream. Instead, it stays in the gut, where it is broken down into smaller active parts. This means both the small intestine and colon may be exposed to its effects.\n\nUntil now, it has been hard to study this because traditional methods only measure one part of the gut at a time. A team at the University of Nottingham has developed MRI scanning methods that can safely and non-invasively measure water content in the small intestine and colon.\n\nThe aim of this pilot study is to use MRI in healthy volunteers to see exactly where linaclotide acts. This knowledge will help optimise future studies in conditions such as cystic fibrosis.",[415],"Cystic Fibrosis (CF)",[417,418,419,420],"linaclotide","cystic fibrosis","gastrointestinal","MRI","2026-04-28",{"date":273,"type":37},{"date":424,"type":37},"2026-03-09",{"date":426,"type":23},"2026-10",{"name":43,"class":44},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":19,"minAge":435,"maxAge":4,"enrollmentInfo":436,"targetDuration":438,"studyType":24,"phases":4,"briefSummary":439,"conditions":440,"keywords":448,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":45},"100608807","in-depth-characterisation-of-biliary-strictures-and-hepato-pancreato-biliary-focal-lesions-for-development-of-new-technologies-to-tackle-hepato-pancreato-biliary-cancers-100608807","NCT07206355","In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers","Map HPB","Inclusion Criteria:\n\n* Aged 16 years and over\n* Ability to provide informed consent to participate in the study\n* Patients attending Nottingham University Hospitals NHS Trust (NUH) as part of standard clinical care for either:\n\n  * the diagnosis and treatment of suspected biliary stricture or any focal lesion in the Hepato-Pancreato-Biliary (HPB) tract (clinically \u002F radiologically) including liver or pancreatic lesion or pancreatic cyst\n  * surgical resection treatment of liver, pancreas, or gall bladder including Whipple Procedure (pancreaticoduodenectomy surgery), gall bladder resection (cholecystectomy), hepatic resection\n\nExclusion Criteria: No exclusion criteria","16 Years",{"count":437,"type":23},160,"5 Years","Hepato-Pancreato-Biliary (HPB) cancers originating in the liver, bile ducts, pancreas, and gall bladder represent a rising global health challenge, with incidence doubling in the UK over the past decade. Cholangiocarcinoma (CCA) and pancreatic cancer are particularly aggressive, often detected late due to non-specific symptoms and difficulties in sampling or imaging. In the UK, CCA affects around 3,000 people annually, with only 13% surviving 3 years, while pancreatic cancer has a 5-year survival of 8.3%. Diagnosis is complicated by the anatomical narrowness of the bile duct and the similarity between malignant and benign strictures. Standard imaging often cannot distinguish between inflammation and cancer, while tissue sampling is challenging, paucicellular, and limited in sensitivity, necessitating repeated biopsies. Yet, accurate characterisation is critical as NICE now recommends targeted therapies (FGFR2, NTRK, MSI-H\u002FdMMR, IDH1 mutations) that require molecular profiling.\n\nBoth CCA and PDAC display high heterogeneity, further complicating treatment. Emerging approaches such as Raman spectroscopy can map malignant tissues by detecting vibrational energy shifts, but require further validation due to weak signals. For focal or cystic HPB lesions not well visualised by conventional imaging, novel modalities like ultra-thin endoscopes with scattering\u002Fabsorption imaging are being developed for improved early diagnosis.\n\nManagement of biliary obstruction frequently involves stenting to restore bile flow, essential for palliation and pre-treatment optimization. However, stent failure from tumour ingrowth, displacement, or erosion remains common, and evidence for best stent use is limited. Novel approaches, including drug-eluting coatings and nanoparticle-mediated wireless treatment delivery, are being investigated.\n\nTo overcome diagnostic and therapeutic barriers, flexible snake-like robotic systems with navigation, sampling, spectroscopy, and treatment capabilities are being developed. These devices, alongside ultra-thin endoscopes and integrated Raman spectroscopy, aim to characterise strictures, generate 3D imaging in ex-vivo HPB tissue, and permit targeted ablation. Parallel work will explore molecular and fluid-based biomarkers (blood, bile, cyst fluid) to support minimally invasive diagnosis and monitoring.\n\nThrough integration of engineering, molecular diagnostics, and device innovation, this transdisciplinary research programme (UKRI and MRC funded) seeks to transform early detection, accurate diagnosis, and novel treatment of HPB cancers, thereby improving outcomes in CCA, pancreatic malignancy, and other clinically similar biliary disorders.\n\nAim:\n\nTo provide a detailed understanding of the characteristics (including clinical and molecular) of liver and pancreatic biliary focal lesions (inflammatory and cancerous) and create a bioresource of liver, pancreas, gallbladder and biliary tract associated tissue and fluids (biopsies, brushings, resected tissues, bile and cyst fluid and blood samples) in order to develop innovative tools for accurate diagnosis and treatment.\n\nStudy Configuration: Prospective Longitudinal Cohort study Setting: Secondary care centre, Nottingham University Hospitals NHS Trust. (NUH).\n\nCo-ordinated by the NIHR Nottingham Biomedical Research Centre Description of interventions: This is an observational study involving collecting tissue or body fluids (such as bile or pancreatic cyst fluid) during clinical care in addition to collection of blood samples (for DNA, serum and plasma) and data collection.\n\nSurplus tissue residual to the requirements for standard care will be stored and used. Additional tissue samples and body fluid samples collected for research at time of clinical investigations will not be increasing the risk of the clinical procedure.\n\nBlood samples will be collected from patients at the time of enrolment in the study. These may be collected before and\u002F or after diagnosis is secured.\n\nDuration of study: Overall duration: 60 months Outcome measures: - To report the proportion of patients where adequate tissue could be retrieved from HPB biopsy to come to definitive diagnosis using standard of care.\n\n* To report the proportion of patients where adequate tissue could be retrieved from biopsy to perform molecular characterisation of HPB samples, beyond standard cyto\u002Fhistology, using advanced optical-spatial technologies currently under development.\n* To report the proportion of patients where definitive diagnosis of mucinous cystic neoplasm could be made in patients with pancreatic cyst using standard care\n* To report the proportion of patients where molecular characterisation beyond standard cyto\u002Fhistology could be made in patients with pancreatic cyst using exploratory new technologies under development through ex-vivo experiments\n* To report the correlation between Raman Spectroscopy and standard cyto\u002Fhistology for identification of cancer in HPB samples",[441,442,443,444,445,446,447],"Biliary Tract Cancer (BTC)","Biliary Tract Cancer (CCA)","Cholangiocarcinoma","Cholangiocarcinoma Cancer","Cholangio Carcinoma","Pancreatic Cancer","Pancreatic Cyst",[449,446,447,450,441,443],"biliary tract cancer","Pancreatic lesions",{"date":367,"type":37},{"date":453,"type":37},"2026-01-25",{"date":455,"type":23},"2030-09-30",{"name":43,"class":44},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":89,"phases":468,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":45},"100608043","early-psychosis-investigating-cognition-100608043","NCT07196423","Early Psychosis: Investigating Cognition","Glutamate Changes as a New Neurocognitive Marker in Psychosis","EPIC","Inclusion Criteria for FEP Group (studies 1a and 1b):\n\nEligibility criteria for first episode psychosis group are as follows:\n\n1. Aged 18-55 years.\n2. Ability to understand and willing to give written informed consent.\n3. Fluent in English to be able to understand all cognitive task instructions and questionnaires.\n4. Current psychotic disorder of less than 5yrs total duration. Defined as meeting DSM-5 criteria consistent with a diagnosis of schizophrenia, schizoaffective disorder, bipolar affective disorder, or severe depression with psychosis.\n5. At least 8 weeks of stable treatment.\n6. Ability to travel to the University of Nottingham for in-person testing.\n\nExclusion Criteria for FEP Group (Studies 1a and 1b):\n\n1. Clinically significant neurological or comorbid psychiatric disorder in the opinion of the investigator.\n2. History of clinically significant head injury\n3. Current harmful use of, or dependence on, psychoactive substances (excluding nicotine) in the opinion of the investigator\n4. Current use of any medication which may interfere with the study in the opinion of the investigator, i.e. any medication that might affect the neurochemicals of interest\n5. Contraindications for MR scanning as assessed by SPMIC screening form and trained scanner operator (e.g. claustrophobia, pregnancy, metal implants, etc.)\n6. Contraindications for transcranial direct current stimulation as assessed by standard screening form (e.g. cardiac pacemaker or other implanted devices, seizures, epilepsy, open head wound, etc.)\n7. Having taken part within the previous month as a participant in a clinical trial that involved taking a drug or having an invasive procedure.\n\nInclusion Criteria for Healthy Matched Controls (Studies 1a and 1b):\n\nMatched healthy control participants will be recruited from a local database of volunteers, from posters and online advertisements.\n\nInclusion criteria (matched controls):\n\n1. Aged 18 - 55 years.\n2. Ability to understand and willing to give written informed consent.\n3. English as first language or fluent in English.\n4. Ability to travel to the University of Nottingham for in-person testing.\n\nExclusion criteria for Health Matched Controls (Studies 1a and 1b):\n\n1. Personal or family history of psychosis.\n2. Clinically significant neurological or psychiatric disorder.\n3. History of clinically significant head injury.\n4. Current harmful use of, or dependence on, psychoactive substances (excluding nicotine and caffeine) in the opinion of the investigator.\n5. Current use of any medication, which may interfere with the study in the opinion of the investigator i.e. any medication that might affect the neurochemicals of interest.\n6. Contraindications for MR scanning as assessed by SPMIC screening form and trained scanner operator (e.g. claustrophobia, pregnancy etc).\n7. Contraindications for transcranial direct current stimulation as assessed by standard screening form (e.g. cardiac pacemaker or other implanted devices, seizures, epilepsy, open head wound, etc.)\n8. Having taken part within the previous month as a participant in a clinical trial that involved taking a drug, being paid an inconvenience allowance, or having an invasive procedure (e.g. venepuncture \\>50ml, endoscopy).\n\nInclusion Criteria for participants with lived experiences of psychosis (Study 2):\n\n1. Aged 18+ years.\n2. Ability to understand and willing to give written informed consent.\n3. Fluent in English to be able to understand and answer all questions.\n4. History of psychotic disorder defined as DSM-5 criteria for diagnosis of schizophrenia, schizoaffective disorder, bipolar affective disorder, or severe depression with psychosis. No limit of time since first episode.\n5. At least 8 weeks of stable treatment.\n6. Ability to travel to the University of Nottingham for in-person testing.\n\nExclusion Criteria for participants with lived experiences of psychosis (Study 2):\n\n1. Clinically significant neurological or comorbid psychiatric disorder.\n2. Current harmful use of, or dependence on, psychoactive substances (excluding nicotine) in the opinion of the investigator.\n3. Having taken part within the previous month as a participant in a clinical trial that involved taking a drug or having an invasive procedure.\n4. Lived experience where psychosis symptoms have not been directly experienced by the individual (e.g., support or carer role to someone else).","55 Years",{"count":467,"type":23},106,[91],"The project aims to explore changes in brain chemistry in individuals who have recently experienced psychosis. Recent research suggests that chemicals in the brain, specifically one called glutamate, may behave differently in people who have experienced psychosis compared to those who have not. It is also known that some individuals with psychosis can find tasks involving memory and attention more challenging. This study aims at understanding how brain chemistry is linked to memory and attention, and if this is different between people who have and have not experienced psychosis.\n\nThe study will also investigate how a commonly used brain stimulation technique might help people with psychosis and other conditions by altering brain chemistry for a very short period. Non-invasive brain stimulation using very weak electrical stimulation has been used to help improve symptoms in individuals with psychosis and many other conditions, and has been shown to alter brain chemistry for a few hours after stimulation. However, it does not work for everyone. It will be investigated if levels of glutamate can predict whether brain stimulation will help an individual or not. In other words, the study investigates if glutamate can be used as a marker for tailoring treatments.\n\nThis project also aims to collect personal experiences or challenges that individuals with psychosis face. This information will be gathered through interviews. This will help to understand what specific difficulties individuals have, such as with certain aspects of memory and attention. The interview will also gather opinions and concerns about brain imaging and brain stimulation and current understandings of chemicals in the brain. For example, the study will explore why individuals may not want to take part in brain imaging or brain stimulation.",[471,472],"First Episode Psychosis (FEP)","Psychosis",[474,475,476,477,478,479,480,481,482],"psychosis","cognition","glutamate","transcranial direct current stimulation","fMRS","first episode psychosis","GABA","working memory","magnetic resonance spectroscopy",{"date":369,"type":37},{"date":485,"type":37},"2026-02-09",{"date":487,"type":23},"2027-08",{"name":43,"class":44},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":18,"sex":495,"minAge":139,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":89,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":45},"100559709","leucine-supplementation-strategies-to-enhance-muscle-anabolic-responses-in-older-age-100559709","NCT06567665","Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age","Inclusion Criteria:\n\n* Male, 65-75 years of age\n* BMI 18-28 kg\u002Fm2\n* Non smoker\n* Not performing regular resistance type exercise\n* Participant is willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* A BMI \\\u003C18 or \\>28 kg·m-2\n* Active cardiovascular disease: uncontrolled hypertension (BP \\> 160\u002F100), angina, heart failure (class III\u002FIV), arrhythmia, right to left cardiac shunt or recent cardiac event\n* Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)\n* Respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease (COPD)\n* Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn\u002F congenital errors of metabolism (e.g. phenylketonuria (PKU), galactosaemia)\n* Active inflammatory bowel disease\n* Acute infection\n* Acute or chronic renal disease\n* Malignancy (or history of malignancy with 5 y)\n* Recent steroid treatment (within 6 mo), or hormone replacement therapy\n* Coagulopathy\n* Musculoskeletal or neurological disorders\n* Known allergies to any of the product ingredients\n* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance","MALE","75 Years",{"count":498,"type":23},10,[91],"Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.",[502],"Muscle Protein Synthesis",[504,505,506],"Aging","Muscle protein synthesis","Leucine",{"date":369,"type":37},{"date":509,"type":37},"2024-08-05",{"date":511,"type":23},"2026-08-05",{"name":43,"class":44},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":18,"sex":495,"minAge":139,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":89,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":45},"100590776","assessing-the-impact-of-a-leucine-enriched-whey-protein-vs-isonitrogenous-whey-on-muscle-protein-synthetic-responses-in-the-rested-and-acute-post-exercise-states-in-older-adults-100590776","NCT06971822","Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults","Inclusion Criteria:\n\nExclusion Criteria:\n\n* A BMI \\\u003C18 or \\>35 kg\u002Fm2\n* Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \\> 160\u002F100), angina, heart failure (class III\u002FIV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke\n* Any metabolic disease\n* Clotting dysfunction\n* A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)\n* Lactose intolerance\n* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance",{"count":22,"type":23},[91],"Occupying \\~45-55% of body mass, skeletal muscle is the largest organ of the body and plays a pivotal role in locomotion, structural support and whole-body metabolic health. Additionally, skeletal muscle serves as the largest reservoir of amino acids (AA), which negatively adapts in states of disease and fasting to provide energy and AAs for vital organs, but also positively adapts to nutrition (i.e. protein consumption) and exercise (i.e. resistance exercise (RE)). With the current global ageing population, pressure on health and social care systems is continuing to mount due to increased frailty and other age-related co-morbidities. Sarcopenia, the loss of muscle mass (atrophy) and function with advancing age, predisposes an individual to an increased likelihood of physical disability, falls\u002Ffractures and mortality. Whilst sarcopenia is multifaceted and has no sole cause, reduced responses to environmental stimuli (namely nutrition (i.e. protein feeding) and exercise) termed \"anabolic resistance\", appears to be a governing role in the progression of age-related muscle atrophy. The maintenance of muscle mass is regulated by the dynamic relationship between muscle protein synthesis (MPS) and muscle protein breakdown (MPB) with anabolic resistance, therefore, centering upon the blunting of increases in MPS and\u002For suppression of MPB.\n\nAged muscle has consistently shown depressed MPS rates following feeding and also exercise when compared to young muscle. Additionally, older individuals need to consume a greater amount of protein compared to younger individuals to drive an MPS increase above baseline levels. This can often prove difficult due to older adults exhibiting increased satiety, likely contributing to the inadequate daily consumption of protein in such populations. Fortifying protein with leucine may, therefore, provide a nutraceutical avenue for combating anabolic resistance in ageing muscle. Leucine, both an essential amino acid (EAA) and branched chain amino acid (BCAA), is the key AA for stimulating MPS via activation of mechanistic target of rapamycin complex 1 (mTORC1), meaning protein rich in leucine may be advantageous to trigger MPS. Recent work has shown that a submaximal protein (10 g) drink enriched with leucine (4.5 g), compared to the non-essential amino acid (NEAA)- alanine (4.5 g), elevated MPS in older individuals, with anabolic signalling also being robustly triggered when administering \\~6g BCAAs contain \\~2.6 g leucine in older adults. However, research has also shown that in the absence of a full AA profile, leucine alone failed to stimulate MPS in postmenopausal women. It, therefore, remains inconclusive whether standalone or adjuvant supplementation of leucine is most effective to sufficiently stimulate MPS across aged populations and it remains to be investigated whether submaximal doses of complete protein enriched with leucine may lead to enhanced muscle anabolism in older adults.\n\nIn this study, we aim to assess the impact of dietary supplementation with a \"super-whey\" (SW) protein (with \\~40% enhanced leucine and \\~20% enhanced EAAs) vs. isonitrogenous whey protein (WP) on muscle protein synthesis (MPS). We will examine these effects both in the rested state, as well as the 24 hour post-exercise period under tightly controlled activity and feeding conditions.",[523],"Healthy Male Volunteers Over 65",[506,525,526,527,528],"Muscle Mass","Sarcopenia","Nutrition","Protein","2026-04-27",{"date":421,"type":37},{"date":532,"type":37},"2025-03-14",{"date":534,"type":23},"2029-02-28",{"name":43,"class":44},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":18,"sex":495,"minAge":139,"maxAge":334,"enrollmentInfo":544,"targetDuration":4,"studyType":89,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":45},"100493046","assessing-the-dose-response-of-muscle-protein-synthesis-to-super-whey-in-older-adults-100493046","NCT05700058","Assessing the Dose-response of Muscle Protein Synthesis to \"Super-whey\" in Older Adults","Assessing the Dose-response of Muscle Protein Synthesis to \"Super-whey\" at Rest and in Response to Acute Exercise in Older Adults","ARLA-WHEY","Inclusion Criteria:\n\n* Participant is in the desired age-ranges (young adults: 18-35 years; older adults: 65+ years).\n* Participant is willing and able to give informed consent for participation in the study.\n* Participant is physically able to perform resistance exercise\n\nExclusion Criteria:\n\n* A BMI \\\u003C18 or \\>35 kg\u002Fm2\n* Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \\> 160\u002F100), angina, heart failure (class III\u002FIV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke\n* Any metabolic disease\n* Clotting dysfunction\n* A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)\n* Lactose intolerance\n* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance",{"count":22,"type":23},[91],"Skeletal muscle accounts for approximately 45-55% of total body mass in healthy adults and plays a pivotal role in whole-body metabolic health, locomotion and physical independence. Undesirable loss of skeletal muscle mass (atrophy) is, however, a common feature of many diseases and scenarios including ageing, bed rest\u002Fimmobilisation, cancer and physical inactivity. Despite the exact mechanisms causing muscle atrophy being not yet fully understood, \"anabolic resistance\" (reduced muscle building in response to protein feeding and exercise) is thought to be key, especially for age-related skeletal muscle losses (known as sarcopenia). As such, the search for optimal strategies (e.g., exercise and\u002F or nutritional interventions) to combat this anabolic blunting remains a hot-topic in scientific research.\n\nLeucine, an essential and branched chain amino acid (EAA\u002FBCAA), is thought to be the most potent AA for stimulating muscle protein synthesis (MPS; the muscle building process). Although, as a stand-alone supplement, leucine is unlikely to provoke a robust and prolonged state of MPS, low doses of leucine-enriched mixed-EAAs can elicit similar increases in MPS as compared to a large dose of whey protein. As reduced appetite and increased satiety (feeling fuller) are common with advancing age, supplementation of a low-dose protein (i.e., leucine-enriched) that can adequately stimulate MPS may contribute to muscle health maintenance in older adults and reduce satiation following a meal.\n\nThis study aims to examine which of three doses of a novel leucine-enriched whey protein (\"super-whey\") best stimulates muscle building in older adults",[526],{"date":344,"type":37},{"date":550,"type":37},"2023-01-31",{"date":426,"type":23},{"name":43,"class":44},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":45},"100550402","drug-induced-liver-injury-itching-study-100550402","NCT06446609","Drug-induced Liver Injury: Itching Study","Understanding the Natural History and Impact of Itching (Pruritus) in Patients With Drug-induced Liver Injury (DILI)","Inclusion Criteria:\n\n* Age ≥18 (no upper age limit) and able to give informed written consent\n* Exposure to potential causal agent and diagnosed with suspected acute DILI defined as meeting one of the following analytical thresholds at enrolment (visit 1):\n\n  * alanine transaminase (ALT) ≥5 times upper limit of normal (ULN) or\n  * alkaline phosphatase ≥2 times ULN or\n  * ALT ≥3 times ULN plus total bilirubin \\>2 times ULN\n\nResults from clinical test samples collected within 36h of visit will be acceptable (as DILI is an acute event, patients are expected to recover or deteriorate quickly so enrolment aligned with diagnostic tests is necessary).\n\nExclusion Criteria:\n\n* Patients with comorbidities of eczema and urticaria associated with pruritus\n* Patients with existing diagnosis of blood-borne viral hepatitis infection (Hepatitis B\u002FC\u002FE)",{"count":561,"type":23},50,"Idiosyncratic drug-induced liver injury (DILI) is an unpredictable adverse hepatic reaction to a medication used in its therapeutic dose. DILI is the second most common cause of itching in adult Hepatology after biliary obstruction. In particular cholestatic or mixed pattern types of DILI (in which bile flow from the liver is impaired) are associated with long-lasting effects as well as reduced quality of life. There is therefore an urgent need to determine the incidence and natural history of itching in DILI and establish a network of centres that will form a basis for a clinical trial to investigate a novel intervention to treat these.",[564,565],"Drug Induced Liver Injury","Pruritus","2026-04-24",{"date":568,"type":37},"2026-04-30",{"date":570,"type":37},"2025-06-30",{"date":572,"type":23},"2028-05",{"name":43,"class":44},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100632799","medication-understanding-in-ms-100632799","NCT07518381","Medication Understanding in MS","Home-based Assessment of Medication Understanding and Use in People With Multiple Sclerosis","MUMS","Inclusion Criteria:\n\n* Adults aged 18 years and over with a confirmed diagnosis of multiple sclerosis\n* Living in the community (not in residential care)\n* Taking at least one prescribed medication\n* Able to provide informed consent or, for those without capacity to provide informed consent, with a consultee available to provide consultee declaration and provide information during home-based medication review\n* Willing and able to participate in a home-based medication review\n\nExclusion Criteria:\n\n* Severe cognitive or communication impairment without a consultee to provide consultee declaration and medication-related information\n* Participants for whom a home visit is deemed unsafe\n* Non-English speakers",{"count":115,"type":23},"The goal of this observational study is to learn how people with multiple sclerosis (MS) understand, organise, and use their medicines at home. The study aims to explore how people take their prescribed and non-prescribed medicines, what challenges they experience, and whether any safety issues arise in day-to-day medication use.\n\nParticipants will take part in one home visit with trained student researchers. During the visit, researchers will review all medicines and supplements the participant uses, ask about routines and any difficulties, check medication packaging with permission, and ask a brief question about memory. No treatment changes will be made. Information will be reviewed by a senior clinician, and any safety concerns will be shared with the participant's usual healthcare team.",[585],"Multiple Sclerosis",[587,588,589,590,591,592,593,594],"polypharmacy","medication use","medication understanding","medication management","multiple sclerosis","adherence","medication burden","home medication review","2026-04-02",{"date":597,"type":37},"2026-04-08",{"date":599,"type":23},"2026-04-15",{"date":601,"type":23},"2026-09-01",{"name":43,"class":44},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":624,"leadSponsor":626,"locationsCount":4},"100632620","action-falls-for-domiciliary-care-100632620","NCT07516054","Action Falls for Domiciliary Care","Adapting and Implementing the Action Falls Programme for Domiciliary Care: A Focus on Rural and Coastal Communities","Inclusion Criteria:\n\nObservations:\n\n* Domiciliary care workers working in the settings and localities in the sample and providing support to older people\n* Social care practitioners working in the settings and localities in the sample\n\nInterviews:\n\n* Older people (65 years and over) supported by domiciliary care and providing support to older people\n* Relatives of older people supported by domiciliary care\n* Social care practitioners\n* Owners of domiciliary care\n* Commissioners and senior decision makers in Lincolnshire County Council and Nottinghamshire County Council\n\nCo-design workshops:\n\n* Domiciliary care workers working in BelleVie Care\n* Older people (65 years and over) supported by domiciliary care\n* Relatives of older people supported by domiciliary care\n* Social care practitioners\n* Owners of domiciliary care\n* Commissioners and senior decision makers in Lincolnshire County Council and Nottinghamshire County Council\n\nExclusion Criteria:\n\n* Lack of capacity to give informed consent",{"count":611,"type":23},65,"Action Falls is a programme that helps older adults avoid falls and injuries. It finds out why someone might fall and suggests ways to help, like checking their medication and encouraging them to stay active. It was created to try and prevent falls in care homes. It includes training for care home staff, a manual, and a checklist of what to look out for and what to do. Home care providers, local care groups, and older adults who live in the community think Action Falls could be useful too, to help reduce the number of falls in older adults who live at home. The investigators have identified that the programme could be particularly useful for older people who are supported by home care services.\n\nThe goal of this project is to develop ways to deliver and keep the programme running for older people supported by home care services. A future study will then try it out and see it helps people manage falls in home care.\n\nThe first part aims to plan and make changes to the current Action Falls programme to make sure it is suitable for use in home care settings. The investigators will do this by\n\n* observing what happens on home care visits\n* asking people who are supported by and who deliver home care how the programme needs to be changed.\n\nIn a future study the investigators will then deliver the programme across home care in Nottinghamshire and Lincolnshire and evaluate how well it has worked. The study will focus on coastal and rural areas.",[614],"Falls",[616,617,618,619,620],"falls","implementation","independence","social care","home care",{"date":622,"type":37},"2026-04-07",{"date":276,"type":23},{"date":625,"type":23},"2028-06",{"name":43,"class":44},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":637,"conditions":638,"keywords":643,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":649,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":653,"locationsCount":45},"100555914","assessing-central-aspects-of-pain-100555914","NCT06518278","Assessing Central Aspects of Pain","Assessing Central Nervous System Contributions to Accelerate Musculoskeletal Pain Diagnosis and Treatment","AsCent","Inclusion Criteria:\n\n* Adults aged 18 years or over.\n* One for more of the following self-reported diagnoses: fibromyalgia, inflammatory MSK condition (e.g., rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis), low back pain, osteoarthritis.\n* MSK diagnosis and pain onset more than 3 months prior to baseline\n* Self-reported pain levels ≥ 3 on a 0 to 10 numerical rating scale where 0 = 'no pain' and 10 = 'worst pain imaginable' on most days in the 3 months before baseline.\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* Terminal\u002Funcontrolled medical or mental health condition that would prevent participants from completing assessments or pose a significant risk to participants or staff.\n* Insufficient understanding of spoken or written English to comply with the requirements of the study protocol.\n* Inability to adhere to the study protocol.",{"count":636,"type":23},250,"BACKGROUND: Chronic pain continues for more than 12 weeks despite medication or treatment. Chronic pain is the main symptom of muscle and joint problems, rarely explained by damage to the muscle and joints alone. Activity in the central nervous system (CNS; nerves, spinal cord, and brain) pathways governs our ability to describe pain intensity and our emotional response to pain. Musculoskeletal conditions (e.g., inflammatory arthritis, osteoarthritis, low back pain, fibromyalgia) share altered CNS pathways, acknowledged by recent classifications of 'primary' and 'nociplastic' pain. Clinically useful tools to diagnose and measure activity and reveal abnormalities in these CNS pathways are needed to improve clinical decisions and accelerate new treatment development. Laboratory pain sensitivity testing and brain imaging confirm the CNS as a primary contributor to pain. These assessments are less acceptable or unfeasible for clinical practice. Simpler clinical pain sensitivity assessments are being developed. The investigators simple Central Aspects of Pain (CAP) questionnaire detects some people with pain sensitivity and knee, rheumatoid arthritis or low back pain. Combining the CAP questionnaire reflecting emotional processing and simpler pain sensitivity assessment, combining two different dimensions should be better than either approach alone.\n\nPURPOSE: To optimise diagnosis and measurement of CNS as the primary contribution to chronic musculoskeletal pain by using the CAP questionnaire and simpler pain sensitivity assessments to ensure timely, effective diagnosis and treatment.\n\nOBJECTIVES: 1. Assess the ease, ability and performance of the combined CAP questionnaire and simpler pain sensitivity assessments to identify CNS as the primary contributor to chronic pain across musculoskeletal conditions.\n\n2\\. Use the CAP questionnaire alone or with substitute measures of activity in CNS pathways, demographic, and clinical variables to indicate pain levels at six and twelve weeks.\n\n3\\. Understand the relationship between CAP and simpler pain sensitivity assessment with laboratory pain sensitivity assessments as a tool to inform the current CNS activity contributing to pain.\n\n4\\. Evaluate associations between the CAP questionnaire and simpler pain sensitivity assessments with patient outcomes.",[639,640,641,642],"Osteoarthritis","Fibromyalgia","Chronic Low Back Pain","Inflammatory Arthritis",[644,645,646,647,648],"Quantitative Sensory Testing","Temporal Summation","Pressure Pain detection Threshold","Conditioned Pain Modulation","Offset Analgesia",{"date":597,"type":37},{"date":651,"type":37},"2024-10-23",{"date":426,"type":23},{"name":43,"class":44},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":89,"phases":663,"briefSummary":664,"conditions":665,"keywords":667,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":45},"100631878","randomised-study-of-web-based-auditory-training-with-varying-perceptual-and-cognitive-demands-on-training-gains-and-generalised-speech-cognitive-and-communication-outcomes-100631878","NCT07506408","Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Generalised Speech, Cognitive, and Communication Outcomes","PLUS-Optimal for Adults With Listening Difficulties: Investigating the Roles of Listening and Thinking Skills in Online Training Across Different Groups","PLUS-Optimal","Inclusion Criteria:\n\n* Adults (aged 18+ years, no upper age limit);\n* Poorer performance on the DTT (SRT of -5.5 dB SNR or higher, as defined by Dawes, 2013) completed without hearing aid(s) for those who typically use them;\n* Non-hearing device users or hearing aid(s) owner;\n* Ability to read and understand English;\n* Ability to provide informed consent;\n* Access to the internet;\n* Access to functional built-in speakers, external speakers, or headphones.\n\nExclusion Criteria:\n\n* Failure to meet inclusion criteria;\n* Having previous auditory training experience;\n* Cochlear implant users.",{"count":289,"type":23},[91],"WP1: PLUS-Auditory Training\n\nThe goal of this experimental study is to better understand how task difficulty affects on-task learning thresholds and generalised benefits in two PLUS auditory training tasks involving perceptual and cognitive learning in adults aged 18+ (no upper age limit) with listening difficulties. The main question it aims to answer is:\n\n* Does adjusting task difficulty in PLUS, by manipulating the perceptual and cognitive demands of the phonemic discrimination and competing speech tasks, affect on-task learning thresholds and off-task performance in adults with listening difficulties?\n\nResearchers will compare the two experimental arms (easy\u002Fhard) to see whether adjusting task difficulty influences on-task learning thresholds and off-task performance.\n\nParticipants will:\n\n* Be randomly assigned to one of two training programs (phonemic discrimination or competing speech) within the two experimental arms (easy\u002Fhard);\n* Perform training for a minimum of 30 minutes per day, 5 days per week, for two weeks (total 10 training sessions, 5 hours of training);\n* Complete pre- and post- training assessments to measure on-task learning performance and change in performance for untrained measures of speech perception, cognition and self-reported outcomes.\n\nWP2: Post-Training Focus Groups\n\nThe goal of this observational study is to gain in-depth qualitative insights into participants' motivations, experiences of task difficulty, and perceived benefits across the PLUS-AT training groups in adults aged 18+ (no upper age limit) with listening difficulties. The main question it aims to answer is:\n\n* How do participants describe their experiences and perceptions of PLUS-AT, particularly regarding task difficulty and self-perceived changes in listening, hearing, thinking, and quality of life?\n\nResearchers will explore participant experiences across the two experimental arms (easy\u002Fhard) to determine whether motivations for seeking auditory training, knowledge and beliefs about auditory training, attitudes toward PLUS-AT difficulty, and self-perceived changes in listening, hearing, thinking, and quality of life differ.\n\nA subset of participants (n = 20) will:\n\n* Be invited from WP1 to join one of four online focus groups (60-90 minutes via Microsoft Teams);\n* Attend the focus group corresponding to their assigned training program (phonemic discrimination or competing-speech) within the two experimental arms (easy\u002Fhard);\n* Share their experiences of completing PLUS-AT.",[666],"Hearing Loss",[668,669,670,666,671,672],"Auditory Training","Speech Perception","Cognition","Listening Difficulties","Intervention","2026-03-27",{"date":675,"type":37},"2026-04-01",{"date":677,"type":37},"2026-03-13",{"date":679,"type":23},"2027-02-01",{"name":43,"class":44},{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":689,"targetDuration":4,"studyType":89,"phases":691,"briefSummary":692,"conditions":693,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":703,"lastUpdatePostDateStruct":704,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":708,"locationsCount":45},"100631236","cft-guided-self-help-intervention-parents-of-autistic-children-100631236","NCT07498049","CFT Guided Self-help Intervention: Parents of Autistic Children","Testing a Compassion-focused Guided Self-help Intervention for Parents of Autistic Children - Single Case Series Design","CFT-GSH-PAC","Inclusion Criteria:\n\n* Participants must be a parent who lives with their autistic child. The parent must be aged 18 years and above and their child must be aged between 6 and 17 years old. The parent participant must have good use of the English language to provide informed consent, access the workbook material, listen to the audio tracks, engage verbally in the support telephone calls and change interviews and complete outcome measures. The child must have a formal diagnosis of autism spectrum disorder as confirmed following assessment by a doctor or practitioner psychologist. Participants must be technology-literate and have access to technology to access video calls for screening and check-in calls as needed.\n\nExclusion Criteria:\n\n* Those who are currently receiving psychological or mental health input from professionals, those experiencing thoughts related to self-harm and\u002For suicide and those who are dependent on alcohol or drugs, those with a learning disability or other cognitive impairment will be excluded from this research.",{"count":690,"type":23},8,[91],"This research will aim to test how practical, achievable and effective a brief, guided, self-help compassion focused intervention is for parents of autistic children aged 6-17 years old.\n\nThe demands of parenting can be rewarding but also challenging, and it is known that parents of autistic children experience additional pressures. As a result of this, parents of autistic children may be more likely to experience increased stress, anxiety, low mood and lower quality of life, compared to those parenting children who are not autistic.\n\nThere has been only a small amount of research so far regarding whether interventions that focus on building compassion, would be beneficial to parents of autistic children. The purpose of this study is to test whether a short, self-guided compassion-focused intervention is practical, achievable and effective for parents of autistic children. The intervention is based on Compassion Focused Therapy (CFT) and involves reading workbook material and listening to audio tracks. There will also be some questionnaires to complete and 30-minute weekly support calls with the lead researcher.\n\nThis intervention was adapted previously, from an intervention for parents in general, to be more suitable and focused on the needs of parents of autistic children. This study will be the first time the adapted intervention has been used by parents.\n\nThe intervention will be tested by 6-8 parents and will be about 13 weeks long. We will collect some demographic data at the start of the study, and there will be the opportunity to complete an evaluation questionnaire.",[694,695,696,697,698,699,700,701,702],"Autism Disorders and Maternal Stress","Autism","Autism Disorder","Autism Spectrum Disorder","Autism in Children","Parent","Parent Mental Health","Parent Stress","Parent Support","2026-03-23",{"date":673,"type":37},{"date":706,"type":23},"2026-04",{"date":222,"type":23},{"name":43,"class":44},""]